CEROW — CERO THERAPEUTICS HOLDINGS, INC.
—
OTC ·
Health Care ·
Biotechnology ·
CIK 1870404 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -3,846,466 | -1,028,830 | 1,899,971 | 937,512 | 32,405,268 |
| Mar 2026 | 0 | — | -4,845,728 | -5,885,914 | 2,205,110 | 857,489 | 11,463,865 |
| Dec 2025 | 0 | — | -4,426,248 | -4,540,621 | 3,641,134 | 1,662,380 | 9,087,596 |
| Sep 2025 | 0 | — | -4,362,579 | -4,856,395 | 3,911,394 | 2,022,072 | 8,454,556 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-14,395,640
Investing CF
$0
Financing CF
$9,549,592
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
—
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-96,724,029
Inventory
—
Receivables
—
ST Investments
$500,000
EBIT TTM
$-19,939,546
Pretax Income TTM
$-20,700,245
Interest Exp TTM
$166,286
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -19,326,699 | -19,920,262 | 3,641,134 | 9,087,596 | -5,446,462 | -16,080,250 |
| Dec 2024 | — | — | — | 6,206,929 | 8,101,492 | -1,894,563 | — |
| Dec 2023 | 0 | -7,675,049 | -7,289,577 | 5,126,302 | 47,183,997 | -42,057,695 | -5,789,987 |
| Dec 2022 | 0 | -11,971,231 | -11,829,116 | 11,349,488 | 46,220,268 | -34,870,780 | -11,709,311 |
| Dec 2021 | 0 | -11,616,331 | -10,629,620 | — | — | — | -10,094,380 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMGN | AMGEN INC | $224.15B | $414.61 | — |
| GILD | GILEAD SCIENCES, INC. | $187.15B | $150.93 | — |
| MRNA | Moderna, Inc. | $79.40B | $198.88 | — |
| ARGX | ARGENX SE | $59.67B | $959.49 | — |
| RVMD | Revolution Medicines, Inc. | $43.93B | $204.97 | — |
News headlines (Yahoo Finance, 1h cache)
CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial
2026-04-14 12:15 · Yahoo
SRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers
2026-08-31 11:30 · Yahoo
CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors
2026-02-17 13:00 · Yahoo
CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient
2026-02-04 14:05 · Yahoo
CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplas
2026-01-07 14:09 · Yahoo
CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1)
2025-12-17 13:00 · Yahoo
CERo Therapeutics Announces Trading on OTCQB Market
2025-12-02 12:30 · Yahoo
CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing
2025-11-05 13:00 · Yahoo
CERo Therapeutics Announces Listing on OTC Markets
2025-11-03 13:00 · Yahoo
CERo Therapeutics Announces Receipt of Nasdaq Panel Determination
2025-10-29 23:22 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.